Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic …
WEB6 days ago — GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 13% sales growth and strategic innovations in R&D, contrasted with ...
GSK’s ex-vaccines chief says its jab for a flu-like ... - Financial Times
WEB1 day ago — Remove from myFT. GSK ex-vaccines chief says group’s blockbuster flu jab is too expensive. Emmanuel Hanon criticises former company’s vaccine after he raises $100mn for rival product. Emmanuel ...
GSK Announces Positive Topline Data on Co-Administration of …
WEBPHILADELPHIA, September 18, 2024--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) when co-administered with SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted), both AS01-adjuvanted vaccines ...
Press releases | GSK US
WEBUS FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit.
GSK delivers strong 2023 performance and upgrades growth …
WEBJan 31, 2024 — Broad-based performance drives sales, profits and earnings growth: Total 2023 sales £30.3 billion +5% and +14% ex COVID. Vaccines sales +25%, +24% ex COVID. Shingrix £3.4 billion +17%, Arexvy £1.2 billion.
GSK makes a strong start to 2024 with improving outlook for the …
WEBMay 1, 2024 — Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%) Dividend declared of 15p for …
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 — GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.
GSK News
WEBStay updated on the latest news from GSK, a global healthcare company with innovative medicines, vaccines and consumer products.
GSK shares fall as US narrows age recommendation for RSV vaccines
WEBJun 27, 2024 — GSK shares fell more than 6 per cent on Thursday morning after US health officials recommended restricting the use of vaccines for respiratory syncytial virus, an area in which the British ...